THU0034 High Serum Levels of IFN-Lambda1/3 and IFN-Alpha Characterize Two Separate Sub-Groups among SLE Patients
Background SLE is a systemic autoimmune disease with heterogeneous clinical manifestations and still not completely dissected pathogenesis. Both the innate and the adaptive immune systems are dysregulated. IFN-α is known as an important cytokine driving disease manifestations in a subgroup of patien...
Gespeichert in:
Veröffentlicht in: | Annals of the rheumatic diseases 2014-06, Vol.73 (Suppl 2), p.188 |
---|---|
1. Verfasser: | |
Format: | Artikel |
Sprache: | eng |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | Background SLE is a systemic autoimmune disease with heterogeneous clinical manifestations and still not completely dissected pathogenesis. Both the innate and the adaptive immune systems are dysregulated. IFN-α is known as an important cytokine driving disease manifestations in a subgroup of patients, and type III IFNs (IFN-λ1, -2 and -3) have recently been described to be associated with renal involvement (1). Objectives We studied circulating levels of IFN-α and IFN-λ1/3 and their association with clinical and laboratory manifestations in a large cohort of SLE patients. Population controls were investigated as comparators. Methods 261 SLE patients and 276 population controls, identified through the population registry and matched for age, sex, and region of living, were included. All participants were investigated clinically by a rheumatologist regarding present and previous organ manifestations. Sera were collected after over-night fasting at inclusion and stored at -70°C until analysis. IFN-α and IFN-λ1/3, levels were measured in sera by commercial ELISA (pan IFN-α and IFN-λ1/3, lowest detection limit 0.022 pg/l and 0.3 pg/l respectively). Results IFN-α was detected in 154 (59%) patients and IFN- λ1/3 in 76 (29,1%) and 79 patients (30%) hade no detectable levels of any of those. In comparison to controls, patients had higher levels of both IFN-α and IFN- λ1/3 p1.3 pg/l) levels of IFN-λ1/3 (n=37) and the other with high (>0.112pg/l) IFN-a levels (n=39) (see figure). There were only 5 patients (cross symbol in the figure) who had high levels of both cytokines. For further statistical analysis patients were grouped accordingly to the figure. Patients with high IFN-λ1/3 levels were compared to the patients with high IFN-α and to the rest of the patients. Statistical analysis included occurrence of common clinical SLE manifestations and autoantibodies. Both IFN-α and IFN- λ1/3 high groups had leukopenia (likelihood ratio (LR), p |
---|---|
ISSN: | 0003-4967 1468-2060 |
DOI: | 10.1136/annrheumdis-2014-eular.5823 |